MEDX Oncology East

Session 2: Achieving Precision Care in Gastrointestinal Cancers

Thursday, September 7     9:15am – 11:15am


Treatment selection is largely dependent on the goals of therapy; however, sequencing of standard therapies with newly approved therapies as patients progress is a key factor in improving quality of care. The approval of new agents and advances in mutation analysis have supported the individualization of treatments and subsequent improvements in survival for patients with gastrointestinal cancer. Despite significant advancements in supportive care and updates to treatment guidelines, many oncologists do not understand the implications of each treatment option stunting the proper use of these agents.

It is essential for oncologists to increase their capacity to individualize treatment by making complex treatment selections based on mutation status, safety and efficacy, and prior treatment while ensuring quality measures, documentations, and guidelines are met. As new agents are expected to enter the treatment paradigm in 2017, clinicians will require guidance on how to best integrate these agents and navigate reimbursement and quality requirements of new payment models.

Case-based Format

Faculty will discuss 3 patient stories to highlight the factors that impact treatment decisions in GI cancers. The clinical case discussions will reinforce learning and provide an opportunity for the participants to apply their knowledge in a practical setting. Content of the case discussions will be focused around established clinical practice guidelines, phase III practice-changing data with Level 1 evidence, and currently recruiting clinical trials. Faculty will provide evidence-based rationales for treatment choices at each decision point in the cases and incorporate relevant quality measures and OCM/MACRA requirements.

An interactive discussion featuring the use of iPad ARS and covering the following topics:

  • Case 1: Unresectable Metastatic Colorectal Cancer
    • Refining 1st-line and 2nd-line treatment options for RAS mutant and wild-type mCRC
    • Implications for MSI-H metastatic CRC
  • Case 2: Unresectable Hepatocellular Cancer
    • Systemic therapy
    • 2nd-line therapy for HCC
    • Novel agents in clinical trials
  • Case 3: Gastric Cancer
    • Prognosis based on molecular subtype
    • Personalizing chemotherapy regimens
    • Immunotherapy for GEJ cancers


Mickey Mouse

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Donald Duck

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.